| 93.498 |
Provider Relief Fund and American Rescue Plan (arp) Rural Distribution |
$50.60M |
| 93.121 |
Oral Diseases and Disorders Research |
$2.07M |
| 84.268 |
Federal Direct Student Loans |
$1.59M |
| 32.006 |
Covid-19 Telehealth Program |
$1.32M |
| 12.RD |
The Mobility Toolkit: Electronically Augmented Assessment of Functional Recovery Following Lower-Extremity Trauma |
$916,072 |
| 93.253 |
Poison Center Support and Enhancement Grants |
$520,967 |
| 93.840 |
Primary Care Implementation and Evaluation of Coach McLungs™ An Asthma Shared Decision-Making Intervention, Across A Large Healthcare System |
$440,590 |
| 93.889 |
Metrolina Healthcare Preparedness Region 22-23 |
$407,320 |
| 84.063 |
Federal Pell Grant Program |
$393,436 |
| 21.027 |
Coronavirus State and Local Fiscal Recovery Fund |
$389,570 |
| 93.391 |
Community Health Workers Model 2021-2023 |
$374,207 |
| 93.958 |
Implementing A Coordinated Specialty Care (csc) Model Program in Mecklenburg County – Block Grants for Community Mental Health Services |
$372,054 |
| 12.420 |
The Major Extremity Trauma Research Consortium (metrc) |
$356,647 |
| 12.420 |
Injury Risk in Special Forces Operations |
$349,399 |
| 93.958 |
First Episode Psychosis Program |
$326,195 |
| 93.361 |
Nursing Research |
$323,034 |
| 93.395 |
Dual Pi3k/brd4 Inhibitory Chemotype for Maximum Inhibition of Myc and Cancer |
$308,104 |
| 93.137 |
Minority Systemic Lupus |
$292,445 |
| 93.078 |
Through Military-Civilian Partnerships at Atrium Health's Carolina Medical Center |
$285,000 |
| 84.425E |
Covid-19 – Heerf Education Emergency Relief Fund (heerf) Student Aid Portion |
$280,330 |
| 93.323 |
Birth Defects and Developmental Disabilities – Prevention and Surveillance |
$196,736 |
| 93.273 |
Alcohol Research Programs |
$173,509 |
| 93.837 |
Metabolic Pathways to Cardiovascular Disease |
$173,473 |
| 93.686 |
Recast Training |
$172,604 |
| 93.396 |
Role of Pten and Pi-3 Kinase in Medulloblastomagenesis |
$157,723 |
| 16.575 |
Stanly Butterfly House 2022-2024 |
$152,976 |
| 93.488 |
Emergency Medicine Service Line |
$144,572 |
| 93.145 |
Hiv Linkage |
$131,477 |
| 93.323 |
North Carolina Coronavirus Variant Sequencing (corvaseq) Initiative |
$123,784 |
| 93.866 |
Pragmatic Evaluation of Events and Benefits of Lipid-Lowering in Older Adults (preventable) |
$117,155 |
| 16.575 |
Cabarrus – Jeff Gordon Children’s Advocacy Center 2022-2024 |
$116,427 |
| 93.994 |
Perinatal/neonatal Program (2023-2024) |
$114,109 |
| 12.420 |
The Major Extremity Trauma and Rehabilitation Research Consortium |
$113,879 |
| 93.137 |
Speech Profiles and Cue Responsiveness After Left Hemisphere Stroke |
$111,198 |
| 16.320 |
Services for Trafficking Victims |
$93,894 |
| 93.395 |
Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans |
$91,308 |
| 93.994 |
Perinatal/neonatal Program Region III |
$83,363 |
| 93.914 |
Ryan White – Part A |
$78,354 |
| 12.420 |
Metrc III |
$76,092 |
| 93.137 |
Covid-19 Resources with Ahec |
$75,437 |
| 93.323 |
Public Health Epidemiologist 2022-2023 |
$73,713 |
| 20.600 |
T- Sbirt - Traffic Counseling Toward Impaired Drivers and Seatbelt Use in A Trauma Center (2022-2023) |
$71,633 |
| 93.958 |
Project Seed Expansion |
$71,158 |
| 12.420 |
Prophylactic Nail |
$68,274 |
| 93.846 |
The Local Infiltration Therapy (lit) Trial for Pain Control Following Hip Fracture Fixation |
$66,613 |
| 93.365 |
Sickle Cell Treatment Demonstration Program |
$58,932 |
| 12.420 |
Effect of Early Weight Bearing |
$57,705 |
| 93.958 |
Cbcrp Pilot |
$49,469 |
| 93.865 |
A Randomized Controlled Trial of Frozen Embryo Transfers Performed in Modified Natural Versus Programmed Cycles (natpro) |
$47,390 |
| 93.865 |
Using Interactive Virtual Presence to Remotely Assist Parents with Child Restraint |
$46,725 |
| 10.310 |
A Nutrimetabolomics Approach to Identify the Biomarkers of Whole Grain Intake |
$46,088 |
| 93.914 |
Covid-19 – Hiv Emergency Relief Project Grants |
$45,863 |
| 93.847 |
Aldh1l1 Polymorphisms in Regulation of Glycine Metabolism |
$40,435 |
| 93.394 |
Cancer Detection and Diagnosis Research |
$40,184 |
| 93.837 |
Heartshare |
$35,597 |
| 93.RD |
A Phase Ii, Single-Stage, Single Arm Investigation of Oral Valganciclovir Therapy in Infants with Asymptomatic Congenital Cytomegalovirus Infection |
$35,535 |
| 93.855 |
A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients with Complicated S. Aureus Bacteremia |
$29,375 |
| 93.226 |
Personalized Clinical Decision Support to Improve Participation in Hospital at Home |
$26,378 |
| 93.839 |
Blood and Marrow Transplant Clinical Trials Network |
$26,283 |
| 84.007 |
Federal Supplemental Education Opportunity Grant Program |
$25,474 |
| 93.395 |
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer |
$22,800 |
| 93.667 |
Cac Dhhs 2023-2024 |
$21,996 |
| 93.073 |
Birth Defects and Developmental Disabilities – Prevention and Surveillance |
$20,000 |
| 93.395 |
Nrg-Gu009: Parallel Phase III Randomized Trials for High-Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (predict-Rt) |
$19,550 |
| 93.395 |
Phase III Study of Daratumumab/rhuph20 + Lenalidomide Or Lenalidomide As Post-Autologous Stem Cell Transplant |
$18,972 |
| 93.558 |
2022-2023 Cacnc Butterfly House Dhhs |
$18,374 |
| 93.855 |
Congenital and Perinatal Infections Rare Diseases |
$18,000 |
| 93.360 |
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus |
$17,795 |
| 20.600 |
T- Sbirt - Traffic Counseling Toward Impaired Drivers and Seatbelt Use in A Trauma Center |
$17,040 |
| 93.839 |
Sickle Cell Disease and Cardiovascular Risk – Red Cell Exchange Trial (scd-Carre) |
$16,821 |
| 93.889 |
North Carolina Covid-19 Hospital Preparedness Program |
$16,500 |
| 93.395 |
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (tip) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin |
$15,900 |
| 93.395 |
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Mk-3475 (pembrolizumab) As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/=1 Cm Residual Invasive Cancer Or Positive Lymph Nodes (ypn+) After Neoadjuvant Chemotherapy |
$14,790 |
| 93.667 |
Dhhs Cabarrus Jeff Gordon 2023-2024 |
$14,780 |
| 93.884 |
Primary Care Training Enhancement (pcte) |
$14,627 |
| 93.310 |
Trials and Research Network for Even More (transform-2) |
$14,046 |
| 93.080 |
Public Health Surveillance for the Prevention of Complications of Bleeding Disorders |
$13,957 |
| 93.853 |
Sleep Smart |
$12,545 |
| 93.127 |
Pecarn |
$11,232 |
| 93.395 |
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgeryin Patients with Resectable Brain Metastases |
$10,800 |
| 93.421 |
Pediatric Public Health Partnership on Fetal Alcohol Spectrum Disorders |
$10,000 |
| 93.395 |
Phase III Randomized Trial of Standard Systemic Therapy (sst) Versus Standard Systemic Therapy Plus Definitive Treatment (surgery Or Radiation) of the Primary Tumor in Metastatic Prostate Cancer |
$9,450 |
| 93.847 |
Gene Discoveries in Subjects with Crohn's Disease of African Descent |
$9,257 |
| 93.853 |
Strategies to Innovate Emergency Care Clinical Trials Network (siren) |
$8,886 |
| 93.853 |
Pediatric Dose Optimization for Seizures in Ems (pedidose) |
$8,815 |
| 93.395 |
Preoperative Thp and Postoperative De-Escalation in Patients Who Achieve A Pathologic Complete Response |
$8,725 |
| 93.395 |
A Randomized Phase Iii, Two-Arm Trial of Paclitaxel/carboplatin/maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-Iv, Primary Low-Grade Serous Carcinoma of the Ovary Or Peritoneum |
$8,250 |
| 93.838 |
The Capture Study: Validating A Unique Copd Screening Tool in Primary Care |
$8,215 |
| 93.839 |
A Comparison of Individualized Vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease (compare-Voe) |
$7,980 |
| 93.395 |
A Randomized Phase Ii/iii Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal |
$7,875 |
| 93.399 |
National Surgical Adjuvant Breast and Bowel Project |
$7,725 |
| 93.395 |
Nrg-Lu005: Limited Stage Small Cell Lung Cancer (ls-Sclc): A Phase Ii/iii Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab |
$7,001 |
| 93.395 |
National Surgical Adjuvant Breast and Bowel Project (nsabp)/radiation Therapy Oncology Group (rtog)/gynecologic Oncology Group (gog) |
$7,000 |
| 93.395 |
Southwest Oncology Group Network Group Operations Center of the Nctn |
$6,700 |
| 93.RD |
Research on Viral Infections |
$6,019 |
| 93.433 |
Traumatic Brain Injury Model Systems National Data and Statistical Center |
$6,000 |
| 93.RD |
Alliance for Clinical Trials in Oncology |
$5,900 |
| 93.866 |
A Multifaceted Digital Health Platform to Advance Alzheimer's Disease Patient Monitoring, Safety, Caregiving, and Research |
$5,673 |
| 93.853 |
Statins Use in Intracerebral Hemorrhage Patients (saturn) Study |
$5,627 |
| 93.395 |
Randomized Trial of Standard Chemotherapy Alone Or Combined with Atezolizumab As Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient Dna Mismatch Repair |
$4,804 |
| 93.395 |
Randomized Phase Ii/iii Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, Or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck |
$4,350 |
| 93.837 |
Coronary Artery Calcium in Pragmatic Evaluation of Events and Benefits of Lipid-Lowering in Older Adults (cac Preventable Ancillary Study) |
$3,500 |
| 93.110 |
Hemophilia Treatment Centers (sprans Yr5-10) |
$3,420 |
| 93.395 |
Randomized Phase Ii/iii Trial of Radiotherapy with Concurrent Durvalumab Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-Ivb Head and Neck Cancer with A Contraindication to Cisplatin |
$3,195 |
| 93.RD |
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance |
$3,000 |
| 93.395 |
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (dawt) and Relapsed Favorable Histology Wilms Tumors (fhwt) |
$2,700 |
| 93.839 |
Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using MacHine Learning Models (premier) |
$2,642 |
| 12.420 |
Novel Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fracturesat High Risk of Infection: Tobra -A Multicenter Randomized, Controlled Trial |
$2,250 |
| 93.395 |
A Phase Iii, Randomized Study of Nivolumab (opdivo) Or Brentuximab Vedotin (adcetris) Plus Avd in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lympho |
$2,100 |
| 93.853 |
Transnasal Cooling for Migraine |
$2,020 |
| 12.420 |
Randomized Trial of Early Hemodynamic Management of Patients Following Acute Spinal Cord Injury – Temple |
$2,000 |
| 93.360 |
Biomedical Advanced Research and Development Authority (barda), Biodefense Medical Countermeasure Development |
$1,917 |
| 12.420 |
Effect of Early Weight Bearing on Rehabilitation |
$1,876 |
| 93.837 |
Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (the Compass Trial) |
$1,875 |
| 93.847 |
Neptune 3 |
$1,408 |
| 93.395 |
Children’s Oncology Group |
$1,100 |
| 93.395 |
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-All; Risk-Adapted Post-Induction Therapy for High-Risk B-All, Mixed Phenotype Acute Leukemia, and Disseminated B-Lly |
$1,000 |
| 93.889 |
Metrolina Healthcare Preparedness Region 21-22 |
$985 |
| 12.420 |
Evaluation of A New Strategy for Protocolized Antibiotic Care for Severe Open Fractures |
$891 |
| 93.839 |
Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation (ctrl-Alt-D) Bmt |
$771 |
| 12.420 |
Rehabilitation Enhanced by Partial Arterial Inflow Restriction |
$565 |
| 93.669 |
Cac Dhhs 2023-2024 |
$253 |
| 93.669 |
2022-2023 Cacnc Butterfly House Dhhs |
$209 |
| 93.395 |
A Multicenter Phase II Trial of Paclitaxel with and Without Nivolumab in Taxane Naïve, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma |
$200 |
| 93.669 |
Dhhs Cabarrus Jeff Gordon 2023-2024 |
$170 |
| 93.395 |
Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (sbrt) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (nsclc) |
$150 |
| 93.395 |
A Randomized Phase Ii/iii Trial of Prophylactic Cranial Irradiation with Or Without Hippocampal Avoidance for Small Cell Lung Cancer |
$50 |
| 93.395 |
Phase Ii/iii Study of Circulating Tumor Dna As A Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage Iia Colon Cancer (cobra) |
$50 |
| 93.879 |
Medical Library Assistance |
$-515 |
| 93.136 |
Injury Prevention and Control Research and State and Community Based Programs |
$-18,394 |